Alterity Therapeutics (Alterity Therapeutics) Long-Term Capital Lease Obligation : $0.00 Mil (As of Sep. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Alterity Therapeutics Long-Term Capital Lease Obligation?

Alterity Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.00 Mil.

Alterity Therapeutics's quarterly Long-Term Capital Lease Obligation increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.07 Mil) but then declined from Jun. 2023 ($0.07 Mil) to Sep. 2023 ($0.00 Mil).

Alterity Therapeutics's annual Long-Term Capital Lease Obligation increased from Jun. 2021 ($0.03 Mil) to Jun. 2022 ($0.04 Mil) and increased from Jun. 2022 ($0.04 Mil) to Jun. 2023 ($0.07 Mil).

Alterity Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Alterity Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Long-Term Capital Lease Obligation Chart

Alterity Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.03

0.04

0.07

Alterity Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	0.07	-	-

Alterity Therapeutics (NAS:ATHE) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Alterity Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics (Alterity Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (NAS:ATHE) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PBN:Germany ATH:Australia

Address

350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000

Website

https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.